Skip to main content

Table 2 Odds ratios (ORs) and 95% confidence intervals (95%CI) presenting associations between fold changes in the expression of CTTN, RhoA, ROCK, CLDN-1, CLDN-2, and CLDN-4 genes and axillary lymph node metastasis (ALNM) as a dependent pathological variable of primary non-metastatic BrCa-IDC (no distant metastasis) (n = 173)

From: Profiling the expression of pro-metastatic genes in association with the clinicopathological features of primary breast cancer

Expression levels of gene

ALNM status

 

Crude OR (95%CI)

Adjusted OR (95%CI)

N

Negative

Positive

P-value¥

Negative

Positive

Negative

Positive

CTTN

 <2.31*

72

22 (30.6)a

50 (69.4)

0.282

1.00

0.77

(0.38–1.52)b

1.00

0.94

(0.46–1.92)c

 ≥2.31

77

28 (36.4)

49 (63.6)

 

 <4.88**

85

29 (34.1)

56 (65.9)

0.504

1.00

1.06

(0.53–2.11)

1.00

1.28

(0.62–2.64)c

 ≥4.88

64

21 (32.8)

43 (67.2)

 

RhoA

 <0.69*

86

26 (30.2)

60 (69.8)

0.182

1.00

0.70

(0.37–1.33)

1.00

0.74

(0.39–1.40)d

 ≥0.69

87

33 (37.9)

54 (62.1)

 

 <0.73**

87

26 (29.9)

61 (70.1)

0.155

1.00

0.68

(0.36–1.28)

1.00

0.71

(0.37–1.35)d

 ≥0.73

86

33 (38.4)

53 (61.6)

 

ROCK

 <0.83*

85

31 (36.5)

54 (63.5)

0.353

1.00

1.18

(0.63–2.23)

1.00

3.05

(1.01–9.18)e

 ≥0.83

86

28 (32.6)

58 (67.4)

 

 <1.09**

104

39 (37.5)

65 (62.5)

0.195

1.00

1.41

(0.73–2.71)

1.00

2.18

(0.75–6.33)e

 ≥1.09

67

20 (29.9)

47 (70.1)

 

CLDN-1

 <1.06 *

88

35 (39.8)

53 (60.2)

0.135

1.00

1.49

(0.79–2.81)

1.00

1.55

(0.82–2.95)f

 ≥1.06

85

26 (30.6)

59 (69.4)

 

 <0.75**

37

15 (40.5)

22 (59.5)

0.284

1.00

1.33

(0.63–2.81)

1.00

1.35

(0.63–2.87)f

 ≥0.75

136

46 (33.8)

90 (66.2)

 

CLDN-2

 <1.15*

45

12 (26.7)

33 (73.3)

0.273

1.00

0.57

(0.23–1.37)

1.00

0.54

(0.21–1.37)g

 ≥1.15

49

19 (38.8)

30 (61.2)

 

 <1.12 **

15

6 (40.0)

9 (60.0)

0.363

1.00

1.44

(0.46–4.48)

1.00

1.60

(0.48–5.35)g

 ≥1.12

79

25 (31.6)

54 (68.4)

 

CLDN-4

 <0.85 *

85

29 (34.1)

56 (65.9)

0.503

1.00

0.95

(0.50–1.78)

1.00

0.99

(0.52–1.87)h

 ≥0.85

88

31 (35.2)

57 (64.8)

 

 <0.67 **

67

28 (38.8)

41 (61.2)

0.229

1.00

1.34

(0.70–2.54)

1.00

1.37

(0.72–2.62)h

 ≥0.67

106

34 (32.1)

72 (67.9)

 
  1. The statistically significant finding is shown in italic fonts (P < 0.05)
  2. N number, OR odds ratio, CI confidence intervals, ALNM axillary lymph node metastasis, CTTN cortactin, RhoA ras homolog gene family member A, ROCK rho-associated kinase, CLDN claudin
  3. aData were expressed as number (%)
  4. bLogistic regression analysis was performed
  5. Adjusted for cEducation status (illiterate/middle school/diploma/bachelor and higher) and waist circumference (< 90 cm/90 ≤ cm); dAge at menarche (< 13 year/13 ≤ year) and waist circumference (< 90 cm/90 ≤ cm); eAge at first pregnancy (< 24 year/24 ≤ year) and body mass index (≤ 24.99 kg/m2/25–29.99 kg/m2/30 ≤ kg/m2); fEducation status (illiterate/middle school/diploma/bachelor and higher) and body mass index (≤ 24.99 kg/m2/25–29.99 kg/m2/30 ≤ kg/m2); gEducation status (illiterate/middle school/diploma/bachelor and higher) and number of pregnancy (0-1/2-3/≥ 4); hAge at menarche (< 13 year/13 ≤ year) and number of pregnancy (0-1/2-3/≥ 4)
  6. ¥Chi square test was performed
  7. * Fold changes in the expression of studied genes were categorized based on median values
  8. ** Fold changes in the expression of studied genes were categorized based on the cutoff identified by Youden’s index
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us